Edition:
United States

Amgen Inc (AMGN.O)

AMGN.O on Nasdaq

154.67USD
20 Jan 2017
Change (% chg)

$0.87 (+0.57%)
Prev Close
$153.80
Open
$154.71
Day's High
$155.35
Day's Low
$153.82
Volume
3,067,372
Avg. Vol
3,749,335
52-wk High
$176.85
52-wk Low
$133.64

Select another date:

Mon, Jan 9 2017

Photo

Regeneron CEO says Amgen not putting patients first in patent dispute

Regeneron Pharmaceuticals Chief Executive Len Schleifer on Monday ripped into Amgen Inc for its insistence on blocking sales of a rival Regeneron cholesterol drug while the appeals process in a patent infringement case plays out.

UPDATE 1-Regeneron CEO says Amgen not putting patients first in patent dispute

Jan 9 Regeneron Pharmaceuticals Chief Executive Len Schleifer on Monday ripped into Amgen Inc for its insistence on blocking sales of a rival Regeneron cholesterol drug while the appeals process in a patent infringement case plays out.

Regeneron CEO says Amgen not putting patients first in patent dispute

Regeneron Pharmaceuticals Chief Executive Len Schleifer on Monday ripped into Amgen Inc for its insistence on blocking sales of a rival Regeneron cholesterol drug while the appeals process in a patent infringement case plays out.

CORRECTED-Regeneron CEO says Amgen not putting patients first in patent dispute

Jan 9 Regeneron Pharmaceuticals Chief Executive Len Schleifer on Monday ripped into Amgen Inc for its insistence on blocking sales of a rival Regeneron cholesterol drug while the appeals process in a patent infringement case plays out.

BRIEF-Amgen comments on Delaware court's ruling on PCSK9 patent litigation

* Amgen statement on January 9, 2017, U.S. District court decision

BRIEF-Davita enters into new sourcing and supply agreement with Amgen

* Davita enters into new sourcing and supply agreement with Amgen and initiates 2017 kidney care guidance

BRIEF-Amgen and Davita enter into new sourcing and supply agreement

* Amgen and Davita enter into new sourcing and supply agreement

BRIEF-Amgen, Immatics enter strategic collaboration to develop novel bispecific cancer immunotherapies

* Amgen and Immatics enter strategic collaboration to develop novel bispecific cancer immunotherapies

BRIEF-Court grants permanent injunction for infringement of Amgen's Repatha patents

* Court grants permanent injunction for infringement of Amgen's repatha patents

Sanofi, Regeneron lose bid to overturn Amgen win in patent case

A federal judge on Tuesday refused to throw out a court verdict upholding two Amgen Inc patents related to the company's cholesterol drug, a defeat for Sanofi SA and Regeneron Pharmaceuticals Inc, which make a rival drug.

Select another date: